A recent study in European Urology Oncology focused on mortality risks in patients with prostate cancer based on their Gleason scores and clinical parameters. The Gleason score is used to assess the severity of prostate cancer, with lower scores indicating slower spread. Findings from the ProtecT trial suggested that patients with Gleason grade group 1 disease had low mortality rates over a 15-year follow-up. The study highlighted the importance of identifying patients with unsampled high-risk prostate cancer to predict mortality risk accurately. Patients with specific clinical risk factors should be considered for systematic rebiopsy to improve outcomes and reduce mortality risks associated with prostate cancer.
Source link
Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer
